|
 |
 |
 |
Toxicity mechanism identified for Parkinson's disease
January 05, 2009
Neurologists have observed for decades that Lewy bodies, clumps of aggregated proteins inside cells, appear in the brains of patients with Parkinson's disease and other neurodegenerative diseases. The presence of Lewy bodies suggests underlying problems in protein recycling and waste disposal, leading to the puzzle: how does disrupting those processes kill brain cells? One possible answer: by breaking a survival circuit called MEF2D. Researchers at Emory University School of Medicine have discovered that MEF2D is sensitive to the main component of Lewy bodies, a protein called alpha-synuclein. In cell cultures and animal models of Parkinson's, an accumulation of alpha-synuclein interferes with the cell's recycling of MEF2D, leading to cell death. MEF2D is especially abundant in the brains of people with Parkinson's, the researchers found. The results are scheduled for publication in the Jan. 2, 2009 issue of Science. "We've identified what could be an important pathway for controlling cell loss and survival in Parkinson's disease," says senior author Zixu Mao, PhD, associate professor of pharmacology at Emory University School of Medicine. Further research could identify drugs that could regulate MEF2D, allowing brain cells to survive toxic stresses that impair protein recycling, he suggests. Most cases of Parkinson's disease are termed sporadic, meaning that there is no obvious genetic cause, but there are inherited forms of Parkinson's. Some of these can be linked to mutations in the gene for alpha-synuclein or triplications of the gene. The mutations and triplications cause the brain to produce either a toxic form of alpha-synuclein or more alpha-synuclein than normal. "Somehow it's toxic, but alpha-synuclein isn't part of the cell's machinery of death and survival," Mao says. He and his colleagues began examining how alpha-synuclein influenced MEF2D after a report from another laboratory on disposal of alpha-synuclein by chaperone-mediated autophagy (CMA). During CMA, certain selected proteins are funneled into lysosomes, compartments of the cell devoted to chewing up discarded proteins. Mao and colleagues found that lysosomes isolated from cells will absorb MEF2D protein, and interfering with CMA chemically causes MEF2D levels to rise. MEF2D is a transcription factor, a protein that controls whether several genes are turned on or off. Previous studies have shown MEF2D is needed for proper development and survival of brain cells. To function, MEF2D must be able to bind DNA. The authors found that when CMA is disrupted, most of the accumulated MEF2D can't bind DNA. This may indicate that the protein is improperly folded or otherwise modified. "Even though there's a lot of it, something is making the MEF2D protein inactive," Mao says. Mao and his colleagues found that mice that artificially overproduce alpha-synuclein (a model of Parkinson's disease) have elevated levels of apparently inactive MEF2D in their brains. In addition, MEF2D protein levels were higher in the brains of Parkinson's patients than in controls. Following the influence of alpha-synuclein on MEF2D may be a way to connect the various genetic and environmental risk factors for Parkinson's, even if CMA is not the sole mechanism, Mao says. "It may be that various stresses impact MEF2D in different ways," he says. "We think this work provides an explanation that ties several important observations together." Emory University

|
Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics
by M. Flint Beal (Author), Anthony E. Lang (Author), Albert C. Ludolph (Author)
Neurodegenerative diseases are major contributors to disability and disease, with Alzheimer's and Parkinson's diseases the most prevalent. This major reference reviews the rapidly advancing knowledge of pathogenesis and treatment of neurodegenerative diseases in the context of a comprehensive survey of each disease and its clinical features. The editors and contributors are among the leading experts in the field internationally. Covering basic science, diagnostic tools and therapeutic approaches, the book focuses on all aspects of neurodegenerative disease, including the normal aging process. The dementias, prion diseases, Parkinson's disease and atypical parkinsonisms, neurodegenerative ataxias, motor neuron diseases, degenerative diseases with chorea, iron and copper disorders, and...
|

|
Molecular Mechanisms of Neurodegenerative Diseases (Contemporary Clinical Neuroscience)
by Marie-Francoise Chesselet (Editor)
Marie-Françoise Chesselet, MD, PhD, and a panel of leading researchers and neurologists from industry and academia critically review the most recent advances from different yet complementary points of view. Focusing on Alzheimer's, Parkinson's, and CAG triplet repeat diseases, the authors show how studies of cellular and genetically engineered animal models have enhanced our understanding of the molecular mechanisms of neurodegenerative diseases and may lead to new therapeutics. Topics include the role of Ab toxicity, glial cells, and inflammation in Alzheimer's disease; the formation of abnormal protein fragments across several diseases, the impact of dopamine and mitochondrial dysfunction on neurodegeneration. Authoritative and insightful, Molecular Mechanisms of Neurodegenerative...
|

|
Neurodegenerative Diseases (Advances in Experimental Medicine and Biology)
by Shamim I. Ahmad (Editor)
The editor of this volume, having research interests in the field of ROS production and the damage to cellular systems, has identified a number of enzymes showing ·OH scavenging activities details of which are anticipated to be published in the near future as confirmatory experiments are awaited. It is hoped that the information presented in this book on NDs will stimulate both expert and novice researchers in the field with excellent overviews of the current status of research and pointers to future research goals. Clinicians, nurses as well as families and caregivers should also benefit from the material presented in handling and treating their specialised cases. Also the insights gained should be valuable for further understanding of the diseases at molecular levels and should lead to...
|

|
Neurodegenerative Diseases: From Molecular Concepts to Therapeutic Targets
by Rommy Von Bernhardi (Editor), Nibaldo C. Inestrosa (Editor)
This book discusses in detail the different hypothesis and experimental evidence regarding the neurobiological mechanisms involved in neurodegenerative pathology, with an emphasis in Alzheimer's and Parkinson's disease. Since there are many hypotheses for neurodegenerative diseases, there is a real need for a comprehensive view, allowing for integration of the different views for the pathogenic mechanisms of the disease.
|

|
Neural Transplantation in Neurodegenerative Disease: Current Status and New Directions
by Wiley
|
|
|
Protein Quality Control in Neurodegenerative Diseases (Research and Perspectives in Alzheimer's Disease)
by Yves Christen (Editor)
The health of the proteome depends upon protein quality control to regulate the proper synthesis, folding, translocation, and clearance of proteins. The cell is challenged constantly by environmental and physiological stress, aging, and the chronic expressions of disease associated misfolded proteins. Substantial evidence supports the hypothesis that the expression of damaged proteins initiates a cascade of molecular events that leads to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and other diseases of protein conformation.
|

|
Protein Chaperones and Protection from Neurodegenerative Diseases (Wiley Series in Protein and Peptide Science)
by Stephan N. Witt (Editor), Vladimir Uversky (Editor)
How protein chaperones protect cells from neurodegenerative diseasesIncluding contributions from leading experts, Protein Chaperones and Protection from Neurodegenerative Diseases provides an in-depth exploration of how protein chaperones are involved in shielding cells from toxic aggregated or misfolded protein states that cause ALS, Parkinson's, and related diseases.Examining how different protein chaperones ameliorate the toxicity of proteins that are known to cause neurodegenerative damage, the book addresses both research and clinical perspectives on chaperone and anti-chaperone properties. The intersection of molecular chaperones and neurodegeneration is an intensely studied area, partly because of the potential for manipulating the expression of molecular chaperones to thwart the...
|

|
MANAGEMENT OF PARKINSON'S DISEASE: Strategies, pitfalls, and future directions A concise overview of clinical diagnosis, current therapeutic options, and ... neurodegeneration. (Postgraduate Medicine)
by JTE Multimedia
As the population ages, the incidence of Parkinson's disease is likely to increase. Unfortunately, the diagnosis can be complex, and current treatment options offer symptomatic relief in many patients but no cure for the underlying neurodegeneration. In this article, Dr Hermanowicz offers a concise overview of possible etiologic factors, clinical features, treatment principles and practice, and new therapeutic approaches that may improve management of Parkinson's disease in the future.
Original Publication Date: December 2001
|
|
|
ADULTS WITH NEURODEGENERATIVE DISEASES: Occupational Therapy Practice Guidelines (Aota Practice Guidelines)
by Susan Forwell (Author)
|

|
Inflammation, Lifestyle and Chronic Diseases: The Silent Link (Oxidative Stress and Disease)
by Bharat B. Aggarwal (Editor), Sunil Krishnan (Editor), Sushovan Guha (Editor)
Oxidative stress and inflammation are among the most important factors of disease. Chronic infections, obesity, alcohol and tobacco usage, radiation, environmental pollutants, and high-calorie diets have been recognized as major risk factors for a variety of chronic diseases from cancer to metabolic diseases. All these risk factors are linked to chronic diseases through inflammation. While short-term, acute inflammation generated by the immune system serves a therapeutic role, chronic low-level inflammation that may persist "silently" for decades is responsible for chronic diseases. Inflammation, Lifestyle, and Chronic Diseases: The Silent Link describes the role of dysregulated inflammation in persistent and recurring diseases. It investigates links to lifestyle and presents research...
|
|